Fig 5. Nexrutine^® reduces pAkt expression in prostate tumors.

Sectioned prostate tumors from 20 week samples were probed with antibodies specific to pAkt and p65 NFκB and reviewed by a pathologist blinded to the treatments. Immunoreactivity was scored based on the percentage of stained cells and graded semi-quantitatively as zero (0% stained cells), 1+ (< 10% stained cells), 2+ (10–20% stained cells), 3+ (20–50% stained cells) and 4+ (> 50% cells stained). Representative microscopic photos are at low magnification (200 μm bar) and high magnification (20 μm bar) suggesting reduced expression of pAkt indicative of a potential mechanism of action in reducing high grade tumors in Nexrutine^® fed mice.